Etravirine plus Darunavir/r as Dual Therapy
INROADS Trial

Etravirine + Darunavir/r as Dual Therapy
INROADS: Design

Study Design: INROADS

- **Background**: Phase 2b, single-arm trial evaluating etravirine with darunavir plus ritonavir in treatment-experienced subjects or treatment-naïve persons with HIV and with transmitted drug-resistant HIV

- **Inclusion Criteria (n = 54)**
  - Age ≥18 years
  - Treatment-naïve: resistance to either efavirenz or nevirapine, but no resistance to etravirine darunavir
  - Treatment-experienced subjects
  - HIV RNA >500 copies/mL
  - CD4 count ≥50 cells/mm^3

- **Treatment Arms (all taken once daily)**
  - Etravirine 400 mg + Darunavir 800 mg + RTV 100 mg

Etravirine + Darunavir + Ritonavir
(n = 54)

* INROADS = **I**ntelence a**N**d p**R**ezista **O**nce **A** **D**ay **S**tudy

National HIV Curriculum

Etravirine + Darunavir/r as Dual Therapy
INROADS: Result

Week 48: Virologic Response

CVR = confirmed virologic response; TLOVR = Time to loss of virologic; ITT: Intent-to-Treat.
CVR allows patients who are resuppressed after failure to be counted as virologic responders.

Source: Ruane PJ, et al. HIV Med. 2015;16:288-96.

National HIV Curriculum

Etravirine + Darunavir/r as Dual Therapy
INROADS: Conclusions

Conclusions: "Etravirine 400 mg and darunavir/ritonavir 800/100 mg as a two-drug once-daily regimen in treatment-experienced subjects or treatment-naïve subjects with transmitted resistance was virologically efficacious and well tolerated."

National HIV Curriculum

Acknowledgment

The **National HIV Curriculum** is an AIDS Education and Training Center (AETC) Program supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) as part of an award totaling $800,000 with 0% financed with non-governmental sources. This project is led by the University of Washington's Infectious Diseases Education and Assessment (IDEA) Program.